UPDATE | November 11, 2026

Why glycosylation control is no longer a secondary concern in the development of complex biologics

  • MAIL

In an article in Genetic Engineering & Biotechnology News (GEN), Sojeong Lee, Director of Upstream Development, highlights why glycosylation control has shifted from a downstream adjustment to an early-stage upstream priority. Next-generation modalities, such as bispecific antibodies and ADCs, are highly sensitive to glycan heterogeneity, which directly impacts safety and efficacy. Because 80% of glycan variation is clone-dependent, implementing high-throughput screening, Quality-by-Design (QbD) principles, and robust statistical models during early development is essential to minimize clinical and regulatory risks. 


Read the full article in GEN to explore our upstream development methodologies.

In an article in Genetic Engineering & Biotechnology News (GEN), Sojeong Lee, Director of Upstream Development, highlights why glycosylation control has shifted from a downstream adjustment to an early-stage upstream priority. Next-generation modalities, such as bispecific antibodies and ADCs, are highly sensitive to glycan heterogeneity, which directly impacts safety and efficacy. Because 80% of glycan variation is clone-dependent, implementing high-throughput screening, Quality-by-Design (QbD) principles, and robust statistical models during early development is essential to minimize clinical and regulatory risks. 


Read the full article in GEN to explore our upstream development methodologies.

Share article

  • MAIL

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required